Description: The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies who are manufacturers in the GLP-1 agonist pharmaceutical business or who enable such business. GLP-1 agonists seek to lower blood sugar levels and reduce appetite and promote fullness, with the ultimate potential for weight loss. The fund is non-diversified.
Exchange: NYSE ARCA
Country: US : United States of America
Currency: US Dollar ($)
Category: Health
| Asset Allocation | |||
|---|---|---|---|
| Asset Class | Long % | Short % | Net Assets |
| Stock non-US | 52.36 | 0.00 | 52.36 |
| Stock US | 46.85 | 0.00 | 46.85 |
| Cash | 0.80 | 0.01 | 0.79 |
| Sector Weights | ||
|---|---|---|
| Sector | Equity % | Relative to Category |
| Healthcare | 91.06 | 99.78 |
| Industrials | 4.71 | 0.04 |
| Basic Materials | 3.25 | 0.00 |
| Consumer Defensive | 0.97 | 0.03 |
| World Regions | ||
|---|---|---|
| Region | Equity % | Relative to Category |
| North America | 47.22 | 90.74 |
| Europe Developed | 27.59 | 6.15 |
| Japan | 12.56 | 0.50 |
| United Kingdom | 4.91 | 2.07 |
| Africa/Middle East | 3.86 | 0.10 |
| Asia Emerging | 3.37 | 0.34 |
| Asia Developed | 0.49 | 0.03 |
| Australasia | 0.00 | 0.08 |